Söndag 24 November | 19:05:37 Europe / Stockholm

Prenumeration

Kalender

Tid*
2026-02-05 07:30 Bokslutskommuniké 2025
2025-11-06 07:30 Kvartalsrapport 2025-Q3
2025-07-18 07:30 Kvartalsrapport 2025-Q2
2025-05-06 - Årsstämma
2025-04-29 07:30 Kvartalsrapport 2025-Q1
2025-02-06 07:30 Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-19 - Kvartalsrapport 2024-Q2
2024-05-06 - X-dag ordinarie utdelning CEVI 2.25 SEK
2024-05-03 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-07 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-20 - Kvartalsrapport 2023-Q2
2023-05-08 - X-dag ordinarie utdelning CEVI 2.25 SEK
2023-05-05 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-07 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-07-20 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning CEVI 2.00 SEK
2022-05-11 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-04 - Bokslutskommuniké 2021
2021-10-22 - Kvartalsrapport 2021-Q3
2021-07-20 - Kvartalsrapport 2021-Q2
2021-04-30 - X-dag ordinarie utdelning CEVI 0.75 SEK
2021-04-29 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-10-23 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-06-17 - X-dag ordinarie utdelning CEVI 0.00 SEK
2020-06-16 - Årsstämma
2020-04-22 - Kvartalsrapport 2020-Q1
2020-02-05 - Bokslutskommuniké 2019
2019-10-23 - Kvartalsrapport 2019-Q3
2019-07-16 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning CEVI 1.50 SEK
2019-05-08 - Årsstämma
2019-05-07 - Kvartalsrapport 2019-Q1
2019-02-07 - Bokslutskommuniké 2018
2018-10-23 - Kvartalsrapport 2018-Q3
2018-07-19 - Kvartalsrapport 2018-Q2
2018-05-07 - X-dag ordinarie utdelning CEVI 1.50 SEK
2018-05-04 - Årsstämma
2018-05-03 - Kvartalsrapport 2018-Q1
2018-02-09 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-07-18 - Kvartalsrapport 2017-Q2
2017-05-08 - X-dag ordinarie utdelning CEVI 1.50 SEK
2017-05-05 - Årsstämma
2017-05-04 - Kvartalsrapport 2017-Q1
2017-02-07 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-05-06 - X-dag ordinarie utdelning CEVI 1.50 SEK
2016-05-04 - Årsstämma
2016-05-03 - Kvartalsrapport 2016-Q1
2016-02-12 - Bokslutskommuniké 2015
2015-11-09 - Kvartalsrapport 2015-Q3
2015-07-17 - Kvartalsrapport 2015-Q2
2015-05-07 - X-dag ordinarie utdelning CEVI 1.00 SEK
2015-05-06 - Årsstämma
2015-05-05 - Kvartalsrapport 2015-Q1
2015-02-12 - Bokslutskommuniké 2014
2014-11-05 - Kvartalsrapport 2014-Q3
2014-07-18 - Kvartalsrapport 2014-Q2
2014-05-08 - X-dag ordinarie utdelning CEVI 0.50 SEK
2014-05-07 - Årsstämma
2014-05-06 - Kvartalsrapport 2014-Q1
2014-02-13 - Bokslutskommuniké 2013
2013-10-24 - Kvartalsrapport 2013-Q3
2013-07-17 - Kvartalsrapport 2013-Q2
2013-04-25 - X-dag ordinarie utdelning CEVI 0.40 SEK
2013-04-24 - Årsstämma
2013-04-24 - Kvartalsrapport 2013-Q1
2013-02-14 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-07-18 - Kvartalsrapport 2012-Q2
2012-05-24 - Kapitalmarknadsdag 2012
2012-05-03 - X-dag ordinarie utdelning CEVI 0.40 SEK
2012-05-02 - Årsstämma
2012-04-25 - Kvartalsrapport 2012-Q1
2012-02-14 - Bokslutskommuniké 2011
2011-10-25 - Kvartalsrapport 2011-Q3
2011-07-15 - Kvartalsrapport 2011-Q2
2011-04-27 - X-dag ordinarie utdelning CEVI 0.00 SEK
2011-04-26 - Årsstämma
2011-04-20 - Kvartalsrapport 2011-Q1
2011-02-15 - Bokslutskommuniké 2010
2010-10-27 - Kvartalsrapport 2010-Q3
2010-07-16 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning CEVI 0.00 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-12 - Bokslutskommuniké 2009
2009-10-23 - Kvartalsrapport 2009-Q3
2009-07-15 - Kvartalsrapport 2009-Q2
2009-04-27 - Årsstämma
2009-04-27 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
CellaVision är verksamt inom medicinteknik. Bolagets verksamhet utvecklar och marknadsför bildanalyssystem för diagnostisering av blod och övriga kroppsvätskor. Produkterna ämnar ersätta traditionell mikroskopsanalys. Verksamhet bedrivs på global nivå, främst inom Norden, Europa och Nordamerika, där kunderna består av forskningsinstitut. Huvudkontoret ligger i Lund.
2024-02-06 07:00:00

CellaVision and Sysmex Corporation (“Sysmex”) announces a Strategic Alliance Agreement to reinforce and extend their joint leadership position within hematology and seize new opportunities for optimized diagnostics.

For 20 years CellaVision and Sysmex have had a successful partnership, and with the Strategic Alliance Agreement the parties expand their mutual commitment until 2038. The expansion enables the companies to further streamline laboratory processes and transform the field of digital cell morphology.

Through the agreement, CellaVision and Sysmex strengthen the existing relationship by a deeper and broader collaboration within innovation and collaborative commercialization. Sysmex's leading expertise in hematology, combined with CellaVision's advanced imaging solutions and AI-assisted cell classifications, lays the groundwork for the continued innovation of state-of-the-art offerings. This will gradually expand the addressable market through a mutual commitment to raise the standard of diagnostic certainty globally.

“We are pleased to expand our alliance with CellaVision since 2013. This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology.”

- Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation.

"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey. We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex.”

- Simon Østergaard, President & CEO, CellaVision AB.

About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit www.sysmex.co.jp/en/